Similar articles

• A global rank end point for clinical trials in acute heart failure.

  Felker GM, Maisel AS. Felker GM, et al. Circ Heart Fail. 2010 Sep;3(5):643-6. doi: 10.1161/CIRCHEARTFAILURE.109.926030. Circ Heart Fail. 2010. PMID: 20841546 No abstract available.
• Surrogate and mediating endpoints: current status and future directions.

  Prentice RL. Prentice RL. J Natl Cancer Inst. 2009 Feb 18;101(4):216-7. doi: 10.1093/jnci/djn515. Epub 2009 Feb 10. J Natl Cancer Inst. 2009. PMID: 19211455 No abstract available.
• [Learning from mistakes. Considerations on unsuccessful clinical trials of pharmacological therapies in acute heart failure].

  Frigerio M. Frigerio M. G Ital Cardiol (Rome). 2014 Jan;15(1):13-8. doi: 10.1714/1394.15513. G Ital Cardiol (Rome). 2014. PMID: 24503729 Italian. No abstract available.
• The rationale for an acute heart failure syndromes clinical trials network.

  Collins SP, Levy PD, Lindsell CJ, Pang PS, Storrow AB, Miller CD, Naftilan AJ, Thohan V, Abraham WT, Hiestand B, Filippatos G, Diercks DB, Hollander J, Nowak R, Peacock WF, Gheorghiade M. Collins SP, et al. J Card Fail. 2009 Aug;15(6):467-74. doi: 10.1016/j.cardfail.2008.12.013. Epub 2009 Feb 10. J Card Fail. 2009. PMID: 19643356 Review.
• Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.

  Powers JH. Powers JH. Pharmacotherapy. 2005 Dec;25(12 Pt 2):109S-123S. doi: 10.1592/phco.2005.25.12part2.109S. Pharmacotherapy. 2005. PMID: 16305280 Review.